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There is increasing evidence that the presence of an ongoing systemic inflammatory response is associated with poor outcome in
patients undergoing resection for a variety of tumours. The aim of the present study was to examine the relationship between clinico-
pathological status, preoperative C-reactive protein concentration and cancer-specific survival in patients undergoing resection for
gastro-oesophageal cancer. One hundred and twenty patients attending the upper gastrointestinal surgical unit in the Royal Infirmary,
Glasgow, who were selected for potentially curative surgery, were included in the study. Laboratory measurements of haemoglobin,
white cell, lymphocyte and platelet counts, albumin and C-reactive protein were carried out at the time of diagnosis. All patients
underwent en-bloc resection with lymphadenectomy and survived at least 30 days following surgery. On multivariate analysis, only
the positive to total lymph node ratio (hazard ratio (HR) 2.02, 95% confidence interval (CI) 1.44–2.84, Po0.001) and preoperative
C-reactive protein concentration (HR 3.53, 95% CI 1.88–6.64, Po0.001) were independent predictors of cancer-specific survival.
The patient group with no evidence of a preoperative systemic inflammatory response (C-reactive protein p10mgl
 1) had a
median survival of 79 months compared with 19 months in the elevated systemic inflammatory response group (Po0.001). The
results of the present study indicate that in patients selected to undergo potentially curative resection for gastro-oesophageal cancer,
the presence of an elevated preoperative C-reactive protein concentration is an independent predictor of poor cancer-specific
survival.
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Gastro-oesophageal cancer is the third commonest cause of cancer
death in the UK. Each year, there are approximately 16500 new
cases and over 13000 deaths attributable to the disease. Overall
survival is poor with the majority of patients presenting with
advanced, inoperable disease and less than 15% surviving 5 years
(Cancerstats, 2004; www.cancerresearchuk.org). Surgery confers
the greatest chance of long-term cure but is associated with
appreciable morbidity and mortality. As a consequence, potentially
curative surgery is carried out relatively infrequently.
The prognosis for patients who undergo potentially curative
resection is influenced by various pathologic characteristics of the
resected tumour specimen. In particular, residual tumour (R),
lymph node status and the ratio of positive to total lymph nodes
sampled have been shown to have independent prognostic value
(Roder et al, 1994; Siewert et al, 1998).
It is increasingly recognised that it is not only the intrinsic
properties of tumour cells that determine tumour spread but also
the host inflammatory response (Balkwill and Mantovani, 2001;
Coussens and Werb, 2002). Indeed, the systemic inflammatory
response, as evidenced by elevated circulating concentrations of
C-reactive protein, has been shown to be a disease-independent
prognostic factor in a variety of tumours, when resections are
carried out with curative intent (McMillan et al, 2003; Hilmy et al,
2005; Jamieson et al, 2005).
An elevated serum C-reactive protein concentration, before
surgery, has previously been shown to have independent
prognostic value in patients with resectable oesophageal cancer
(Nozoe et al, 2001; Ikeda et al, 2003; Shimada et al, 2003).
However, some of these studies included patients with metastatic
disease at the time of surgery and used variable C-reactive protein
thresholds. To date, the prognostic value of C-reactive protein has
not been examined in patients undergoing potentially curative
resection for gastric cancer.
The aim of the present study was to examine the relationship
between clinico-pathological status, C-reactive protein concentra-
tion, measured before surgery, and cancer-specific survival in
patients selected for potentially curative resection of gastro-
oesophageal cancer.
PATIENTS AND METHODS
Patients
Patients selected for potentially curative resection of gastro-
oesophageal cancer (between January 1996 and December 2004)
and who had a preoperative measurement of C-reactive protein
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swere included in the study. For gastric cancers, tumour node
metastasis (TNM) stage I–III tumours were considered to be
amenable to curative surgical resection. For oesophageal cancers,
TNM stage I–III tumours, excluding T4, were considered to be
amenable to curative surgical resection. Measurements of haemo-
globin, white cell, lymphocyte and platelet counts, albumin and
C-reactive protein were carried out before staging laparoscopy or
surgery. All patients underwent en-bloc resection with lymphade-
nectomy (median 20, range 3–55 nodes resected). All patients were
treated in the upper gastrointestinal (GI) surgical unit at Glasgow
Royal Infirmary and survived at least 30 days following surgery.
Patients undergoing neo-adjuvant chemotherapy or radiotherapy
were excluded.
Data for 1996–1998 (n¼16) were collected retrospectively and
that for 1999–2004 (n¼104) prospectively.
The study was approved by the Research Ethics Committee of
Glasgow Royal Infirmary.
Methods
The extent of tumour spread was recorded using the TNM stage.
Tumours of the gastro-oesophageal junction were further classified
according to site, using the Siewert system; type 1 and 2 lesions of
the gastro-oesophageal junction were designated, as cancers of the
oesophagus. Type 3 tumours of the cardia were designated gastric
cancers.
Routine preoperative laboratory measurements of haemoglobin,
white cell, lymphocyte and platelet counts, albumin and C-reactive
protein were carried out. The coefficient of variation for these
methods, over the range of measurement, was less than 10% as
established by routine quality control procedures. The limit of
detection of the assay is a C-reactive protein concentration of less
than 6mgl
 1, with the upper limit of normal values being
p10mgl
 1. Based on previous work (O’Gorman et al, 2000;
McMillan et al, 2001), a C-reactive protein concentration of greater
than 10mgl
 1 was considered to indicate the presence of a
systemic inflammatory response.
Statistics
Data are presented as median and range. Comparisons between
groups of patients were carried out using contingency table
analysis (w
2) as appropriate. Grouping of the laboratory variables
haemoglobin, white cell, lymphocyte and platelet counts, albumin
and C-reactive protein was carried out using standard thresholds
(O’Gorman et al, 2000; McMillan et al, 2001; Ikeda et al, 2002;
Maltoni et al, 2005; Shen et al, 2005). Survival (cancer-specific)
analysis of the group variables was performed using the Cox
proportional hazard model. Deaths up to the end of February 2006
have been included in the analysis. Multivariate survival analysis,
including all covariates that were significant on univariate analysis,
was performed using a stepwise backward procedure to derive a
final model of the variables that had a significant independent
relationship with survival. To remove a variable from the model,
the corresponding P-value had to be greater than 0.10. Analysis
was performed using SPSS software (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline clinico-pathological characteristics of the patients
(n¼120) studied are shown in Table 1. The majority of patients
were male, under 65 years and had adenocarcinoma. The majority
of patients had localised disease with clear resection margins and
therefore underwent potentially curative surgery (n¼99). Of the
remaining 21 patients, three patients were found to have metastasis
at the time of surgery; one patient with a small bowel deposit, one
patient with a single liver deposit and one patient with metastatic
disease affecting the terminal ileum/ascending colon. The remain-
ing 18 patients had positive circumferential resection margins of
the oesophagus (tumour o1mm from resection margin).
The majority of patients had laboratory-based measures
including haemoglobin, white cell, lymphocyte and platelet counts,
albumin and C-reactive protein concentrations in the normal
range. Fifteen patients (13%) had an elevated circulating C-reactive
protein concentration (410mgl
 1) before surgery.
During the follow-up period, 60 (50%) patients died; 58 of their
disease. The median follow-up of the survivors was 55 months. On
univariate analysis, pTNM stage (Po0.01), lymph node status
(Po0.01), positive to total lymph node ratio (Po0.001) and
preoperative C-reactive protein (Po0.001) were significantly
associated with survival (Table 1). On multivariate analysis of
these significant variables, positive to total lymph node ratio
(hazard ratio (HR) 2.02, 95% confidence interval (CI) 1.44–2.84,
Po0.001, Figure 1) and preoperative C-reactive protein (HR 3.53,
95% CI 1.88–6.64, Po0.001, Figure 2) retained independent
significance.
The preoperative values of C-reactive protein at the thresholds
of 45 and 410mgl
 1 were compared in multivariate survival
analysis. In this analysis, the prognostic significance of the
threshold of 410mgl
 1 (P¼0.013) was greater than 45mgl
 1
(P¼0.559).
The relationship between the presence of an elevated preopera-
tive C-reactive protein concentration and clinico-pathological
characteristics is shown in Table 2. There was no significant
difference in age, sex, tumour site, tumour type, pTNM stage,
presence of positive resection margins, lymph node status, positive
to total lymph node ratio, haemoglobin, white cell, lymphocyte and
platelet counts and albumin groupings between the inflammatory
and non-inflammatory groups. In contrast, a greater proportion of
patients had a lower haemoglobin (Po0.05) and percentage
lymphocyte counts (Po0.001) in the elevated systemic inflamma-
tory response group.
The patient group with no evidence of a preoperative systemic
inflammatory response (C-reactive protein p10mgl
 1) had a
median survival of 79 months compared with 19 months in the
elevated systemic inflammatory response group (Po0.001). The
1- and 2-year survival rates in the patient group with no evidence
Table 1 Clinico-pathological characteristics of patients selected for
potentially curative resection for gastro-oesophageal cancer: univariate
survival analysis
Patients
(n¼120) HR (95% CI) (P-value)
Age (p65/65–74/X75 years) 60/47/13 1.34 (0.92–1.95) 0.132
Sex (m/f) 80/40 1.18 (0.69–2.04) 0.543
Tumour site (oesophageal/gastric) 60/60 1.28 (0.76–2.14) 0.358
Tumour type (adenocarcinoma/
squamous)
100/20 1.24 (0.63–2.47) 0.530
pTNM stage (I/II/III/IV) 32/35/49/4 1.59 (1.15–2.21) 0.006
Resection margin R0/R1 99/19 1.49 (0.79–2.83) 0.218
Lymph node status ( /+) 44/74 2.84 (1.49–5.41) 0.002
Positive to total lymph node ratio
(0/p0.2/40.2)
44/41/33 2.03 (1.45–2.86) o0.001
Haemoglobin (X12/o12gl
 1) 95/23 1.42 (0.76–2.65) 0.267
White cell count (o8.5/8.5–11.0/
411.0 ( 10
9l
 1))
79/30/9 1.05 (0.70–1.58) 0.800
Lymphocyte percentage (20–40/
12–19.9/0–11.9%)
97/17/4 1.38 (0.83–2.30) 0.211
Platelets (o400/X400
( 10
9l
 1))
110/7 0.69 (0.22–2.23) 0.541
Albumin (X35/o35gl
 1) 117/2 0.96 (0.13–7.00) 0.970
C-reactive protein (p10/
410mgl
 1)
105/15 3.51 (1.89–6.53) o0.001
CI¼confidence interval; HR¼hazard ratio.
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sof a preoperative systemic inflammatory response were 83 and
72%, respectively, compared with 67 and 33%, respectively, in the
elevated systemic inflammatory response group.
DISCUSSION
Surgical resection remains the best prospect for long-term survival
in patients with gastro-oesophageal cancer. Currently, in patients
undergoing surgery, prognostic factors are based on the patholo-
gical findings from the resected tumour. However, this means that
the assessment of prognosis occurs after a major operation with
significant morbidity and mortality. Therefore, it is of interest that
in the present study, an elevated circulating concentration of
C-reactive protein (410mgl
 1), measured preoperatively, was
associated with poor survival, independent of the pathological
positive to total lymph node ratio or pTNM stage. In contrast,
neither anaemia, leucocytosis, lymphocytopenia or thrombocytosis
predicted survival in this group of patients undergoing resection
for gastro-oesophageal cancer.
There have been three previous studies from Japan that have
shown the prognostic value of an elevated C-reactive protein
concentration in patients undergoing resection for oesophageal
cancer. However, in contrast with the present study, they included
patients with primarily (490%) squamous tumours (Nozoe et al,
2001; Ikeda et al, 2003; Shimada et al, 2003), patients receiving
neo-adjuvant treatment (Nozoe et al, 2001; Ikeda et al, 2003),
patients who had advanced disease before surgery (Nozoe et al,
2001; Ikeda et al, 2003), they used a threshold for C-reactive
protein of 45mgl
 1 (Nozoe et al, 2001; Ikeda et al, 2003) and the
positive to total lymph node ratio was not assessed (Nozoe et al,
2001; Ikeda et al, 2003; Shimada et al, 2003).
In contrast to the above studies, the majority of patients in the
present study had adenocarcinoma, reflecting the prevailing type
in the Western world. Also, only those patients who underwent
potentially curative resection and did not receive neo-adjuvant
treatment were included in the present study. In these patients, the
positive to total lymph node ratio was prognostic independent of
an elevated C-reactive protein concentration, before surgery.
Therefore, the results of the present study are consistent with
C-reactive protein, measured before surgery, having prognostic
value independent of established pathological criteria in patients
with resectable oesophageal cancer (Nozoe et al, 2001; Ikeda et al,
2003; Shimada et al, 2003). Moreover, we have shown that an
elevated
C-reactive protein concentration, before surgery, is associated with
poor cancer-specific survival in patients undergoing potentially
curative resection for gastro-oesophageal adenocarcinoma.
It was of interest that the threshold for C-reactive protein
(410mgl
 1), which we established in previous studies in patients
with gastro-intestinal cancer (O’Gorman et al, 2000; McMillan
et al, 2001, 2003; Crumley et al, 2006), was superior to that
(45mgl
 1) used in previous prognostic studies in oesophageal
cancer (Nozoe et al, 2001; Ikeda et al, 2003). Moreover, compared
with patients undergoing potentially curative resection for colo-
rectal cancer in the same institution (McMillan et al, 2003),
the proportion of patients who had an elevated circulating
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Figure 1 The relationship between the positive to total lymph node
ratio and cancer-specific survival in patients undergoing resection for
gastro-oesophageal cancer.
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Figure 2 The relationship between the systemic inflammatory response,
as evidenced by C-reactive protein concentrations, and cancer-specific
survival in patients undergoing resection for gastro-oesophageal cancer.
Table 2 The relationship between the presence of a preoperative
systemic inflammatory response and clinico-pathological characteristics of
gastro-oesophageal cancer
C-reactive
protein
p10mgl
 1
(n¼105)
C-reactive
protein
410mgl
 1
(n¼15) (P-value)
Age (p65/65–74/X75 years) 54/39/12 6/8/1 0.721
Sex (m/f) 72/33 8/7 0.244
Tumour site (oesophageal/
gastric)
54/51 6/9 0.410
Tumour type
(adenocarcinoma/squamous)
88/17 12/3 0.712
pTNM stage (I/II/III/IV) 31/29/41/4 1/6/8/0 0.223
Resection margin R0/R1 88/15 11/4 0.235
Lymph node status ( /+) 39/64 5/10 0.736
Positive to total lymph node
ratio (0/p0.2/40.2)
39/35/29 5/6/4 0.891
Haemoglobin (X12/o12gl
 1) 86/17 9/6 0.033
White cell count (o8.5/8.5–
11.0/411.0 ( 10
9l
 1))
71/25/7 8/5/2 0.204
Lymphocyte percentage (20–
40/12–19.9/0–11.9%)
90/11/2 7/6/2 o0.001
Platelets (o400/X400
( 10
9l
 1))
96/6 14/1 0.905
Albumin (X35/o35gl
 1) 102/2 15/0 0.590
Survival (months)
a 79.2 (53.8–104.6) 19.4 (15.3–23.4) o0.001
CI¼confidence interval.
aMedian (95% CI).
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 1) preoperatively
was lower in the present study (13 vs 28%). This probably reflects,
given the increased morbidity and mortality associated with
gastro-oesophageal surgery, a more selective approach than that in
colorectal cancer. Nevertheless, taken together, these results show
the utility of C-reactive protein in the preoperative assessment of
patients undergoing potentially curative surgery for GI cancer.
Indeed, the combination of pathological stage and C-reactive
protein has recently been used to improve the prediction of
outcome in patients who underwent potentially curative resection
for colorectal cancer (Canna et al, 2004).
The basis of the independent relationship between an elevated
C-reactive protein concentration and poor survival in gastro-
oesophageal cancer is not clear. There are a number of possible
explanations. Firstly, that an elevated C-reactive protein identifies
those patients with an impaired T-lymphocytic response, as poor
infiltration of GI tumours appears to be associated with poor
outcome (Schumacher et al, 2001; Ali et al, 2004) and an elevated
C-reactive protein concentration has recently been shown to be
inversely associated with T-lymphocyte subset infiltration (Canna
et al, 2005). Indeed, in the present study, an elevated C-reactive
protein concentration was associated with greater proportion of
patients having lymphocytopenia.
An alternative explanation is that an elevated C-reactive protein
concentration may identify those patients with a proangiogenic
environment, as angiogenesis is associated with poor outcome in
patients with GI tumours (Tanigawa et al, 1997; Fondevila et al,
2004) and circulating concentrations of vascular endothelial
growth factor are directly associated with C-reactive protein
(Xavier et al, 2006). Clearly, both these mechanisms may be related
and promote unrestrained tumour growth and the dissemination
required for the greater malignant potential associated with an
elevated C-reactive protein concentration.
This is a relatively small study in a single centre and requires
verification in large cohorts in other centres. If an elevated C-
reactive protein concentration is confirmed to predict a poorer
prognosis, it may be the case that patients staged to have potentially
resectable gastro-oesophageal cancer, yet a high inflammatory
profile preoperatively, should not undergo surgery. Alternatively,
modulation of the systemic inflammatory response may be a useful
approach in these patients in the preoperative period.
In summary, the results of the present study indicate that in
patients selected to undergo potentially curative resection for
gastro-oesophageal cancer, the presence of an elevated C-reactive
protein concentration preoperatively (410mgl
 1) is an indepen-
dent predictor of poor cancer-specific survival.
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